Dr David Ryan: key facts
- Kind of voice
- Academic
- Role
- MD & PhD student at UCL
- Quoted on
- Diabetes
- Tracked press citations
- 2
- Most recently quoted
- 30 Sept 2026
“Our study shows this drug works very well in a much wider range of people with type 2 diabetes than we previously had evidence for. Our findings support NICE's draft guidance proposing its use as a first treatment for type 2 diabetes, in addition to metformin – which would be a major shift in diabetes care affecting millions.”
What Dr David Ryan has said
“Our study shows this drug works very well in a much wider range of people with type 2 diabetes than we previously had evidence for. Our findings support NICE's draft guidance proposing its use as a first treatment for type 2 diabetes, in addition to metformin – which would be a major shift in diabetes care affecting millions.”
UCL Institute of Health Informatics · Diabetes · 10 Sept 2026 · Wider use of SGLT-2 inhibitors in diabetes ‘could prevent 20,000 deaths a year’, say researchers ↗
Where Dr David Ryan has been quoted
- Patient data show diabetes medicine could save thousands more lives a yearlshtm.ac.uk · 30 Sept 2026
- Wider use of SGLT-2 inhibitors in diabetes ‘could prevent 20,000 deaths a year’, say researcherspulsetoday.co.uk · 10 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.